Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 202, Issue 12, Pages 1656-1665Publisher
AMER THORACIC SOC
DOI: 10.1164/rccm.202007-2794OC
Keywords
COVID-19; idiopathic pulmonary fibrosis; interstitial lung disease; obesity; lung function
Categories
Funding
- National Institute for Health Research (NIHR) Research Professor Award [RP-2017-08-ST2-014]
- NIHR Oxford Biomedical Research Centre
- NIHR [CO-CIN-01]
- Medical Research Council [MC_PC_19059]
- NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool
- Public Health England
- Liverpool School of Tropical Medicine
- University of Oxford (NIHR) [200907]
- Wellcome Trust
- Department for International Development [215091/Z/18/Z]
- Bill and Melinda Gates Foundation [OPP1209135]
- Liverpool Experimental Cancer Medicine Centre [C18616/A25153]
- MRC [MR/V033441/1, MC_PC_19025] Funding Source: UKRI
- UKRI [MR/S032304/1] Funding Source: UKRI
- National Institutes of Health Research (NIHR) [RP-2017-08-ST2-014] Funding Source: National Institutes of Health Research (NIHR)
Ask authors/readers for more resources
Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age-, sex-, and comorbidity-matched population. Methods: An international multicenter audit of patients with a prior diagnosis of ILD admitted to the hospital with COVID-19 between March 1 and May 1, 2020, was undertaken and compared with patients without ILD, obtained from the ISARIC4C (International Severe Acute Respiratory and Emerging Infection Consortium Coronavirus Clinical Characterisation Consortium) cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished idiopathic pulmonary fibrosis from non-idiopathic pulmonary fibrosis ILD and used lung function to determine the greatest risks of death. Measurements and Main Results: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to the hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching, patients with ILD with COVID-19 had significantly poorer survival (hazard ratio [HR], 1.60; confidence interval, 1.17-2.18; P = 0.003) than age-, sex-, and comorbidity-matched controls without ILD. Patients with an FVC of <80% had an increased risk of death versus patients with FVC >= 80% (HR, 1.72; 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR, 2.27; 1.39-3.71). Conclusions: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available